Why Daiichi Sankyo’s Enhertu is drawing so much attention in oncology

Reviewed: ad hoc news Accessory & Components desk. Edited and checked on 2026-06-18, 01:46. Details in the imprint.

With Enhertu, Daiichi Sankyo puts an antibody-drug conjugate on the table that oncologists describe as both powerful and demanding in everyday practice. Patients sit in quiet infusion rooms while a precisely engineered payload hunts down HER2-expressing tumor cells. The promise is more targeted destruction, with toxicity that still needs careful watching.

What Enhertu actually is

Enhertu is the brand name for trastuzumab deruxtecan, an antibody-drug conjugate that links a HER2-targeting antibody to a topoisomerase I inhibitor payload. The construct builds on trastuzumab’s targeting but adds a potent cytotoxic agent designed to be released inside cancer cells.

The drug is co-developed and commercialized globally with AstraZeneca, under a collaboration first signed in 2019 that included multi-billion-dollar upfront and milestone payments. That alliance underlines how central Enhertu has become to both companies’ oncology strategies.

Indications and how doctors use it

Originally, Enhertu entered the market for patients with unresectable or metastatic HER2-positive breast cancer who had received prior anti-HER2 therapies. Over time, regulators extended its reach to earlier treatment lines and additional tumor types beyond breast.

In the United States, the FDA has approved Enhertu for HER2-positive breast cancer, HER2-low breast cancer and certain HER2-mutant or HER2-positive lung cancers, as well as for unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. Comparable indications exist in Europe and Japan, although labels differ in detail between regions.

The surprising HER2-low angle

One of the most discussed updates is the expansion into so-called HER2-low breast cancer, a group that historically did not benefit from classic HER2-targeted therapies. Enhertu’s mechanism and bystander effect enabled efficacy in tumors with lower HER2 expression, opening treatment for a broad new patient segment.

For clinicians, this changed how pathology reports are read in everyday practice. A once marginal detail - a low HER2 score - now potentially unlocks an aggressive therapy option, prompting more careful testing and re-testing of tumor samples.

What the data show at the bedside

In trials, Enhertu has delivered substantial improvements in progression-free survival and overall survival compared with standard treatments in several settings, particularly in heavily pretreated HER2-positive breast cancer. Response rates have been notable, with a high proportion of patients seeing measurable tumor shrinkage.

However, this efficacy profile comes with caveats. Interstitial lung disease and pneumonitis have emerged as key safety concerns, sometimes severe or fatal. Oncologists must monitor respiratory symptoms closely, and some patients require immediate discontinuation if lung toxicity is suspected.

How treatment feels for patients

For patients, Enhertu usually means regular intravenous infusions in hospital day units or specialized oncology centers. The setting is often calm but clinical: drip stands, reclining chairs, a nurse’s watchful eye and conversations hushed around the rhythmic beeping of monitors.

Some patients report fatigue, nausea and hair loss reminiscent of traditional chemotherapy. Others notice subtle differences - slightly less time in the chair, or a pattern of side effects that ebbs and flows between cycles. The emotional weight comes from knowing the drug is both powerful and potentially harsh on the lungs.

Position against competing therapies

In HER2-positive breast cancer, Enhertu competes with a landscape that includes T-DM1 (Kadcyla), pertuzumab combinations and various tyrosine kinase inhibitors. Its strong efficacy has pushed it into earlier lines of therapy in some guidelines, changing the sequence of options.

The HER2-low indication also sets it apart, as fewer alternatives have comparable data in that segment. Yet cost, toxicity management and access restrictions mean it does not simply replace existing regimens; instead, it adds a new, sometimes preferred, choice in complex algorithms.

Pricing, access and where it is used

Enhertu is a high-priced specialty oncology product, typically reimbursed through national health systems or private insurers in major markets such as the US, EU and Japan. Exact list prices vary by country and negotiation, but it clearly sits in the premium biologic bracket.

In Germany and other European states, access usually runs via hospital and specialized oncology centers with prior authorization. In Japan, the home market of Daiichi Sankyo, the drug is available through hospital pharmacies under the national health insurance framework, with usage concentrated in large cancer centers.

Why investors are watching Enhertu

From an investor’s point of view, Enhertu is more than a single product - it is a proof point for Daiichi Sankyo’s broader antibody-drug conjugate platform. Success here strengthens confidence in follow-on candidates against other targets and tumor types.

The economics of the AstraZeneca partnership also matter. Milestone payments, profit-sharing arrangements and potential royalties across multiple indications feed directly into long-term revenue expectations and can offset the high R&D and post-marketing study costs that accompany such a complex therapy.

Company context and stock reference

Daiichi Sankyo is positioning itself as a global oncology specialist, pivoting from a more traditional primary-care portfolio toward targeted cancer medicines anchored by its ADC technology. Enhertu sits at the center of that story, both scientifically and financially.

Shares of Daiichi Sankyo Co Ltd (JP3475350009) trade on the Tokyo Stock Exchange in Japanese yen.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | JP3475350009 | DAIICHI SANKYO | boerse | 69567467 | bgmi